Have a feature idea you'd love to see implemented?
Let us know!
CKPT Checkpoint Therapeutics Inc
Price (delayed)
$2.34
Market cap
$105.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.9
Enterprise value
$100.39M
Checkpoint Therapeutics, Inc. ('Checkpoint') is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is
Highlights
CKPT's EPS has surged by 65% year-on-year and by 31% since the previous quarter
CKPT's net income is up by 28% YoY and by 19% QoQ
Checkpoint Therapeutics's revenue has shrunk by 59% YoY but it has increased by 15% QoQ
CKPT's gross profit has plunged by 59% YoY but it is up by 15% from the previous quarter
The company's quick ratio has shrunk by 55% QoQ and by 4.2% YoY
Key stats
What are the main financial stats of CKPT
Market
Valuations
Earnings
Shares outstanding
45.02M
Market cap
$105.34M
Enterprise value
$100.39M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1,095.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,287.06
Revenue
$78,000
EBIT
-$42.47M
EBITDA
-$42.47M
Free cash flow
-$34.3M
Per share
Balance sheet
Liquidity
EPS
-$1.9
Free cash flow per share
-$0.94
Book value per share
-$0.43
Revenue per share
$0
TBVPS
$0.16
Total assets
$5.67M
Total liabilities
$21.42M
Debt
$0
Equity
-$15.75M
Working capital
-$15.75M
Debt to equity
0
Current ratio
0.26
Quick ratio
0.23
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
-54,444.9%
Gross margin
100%
Net margin
-54,444.9%
Operating margin
-45,501.3%
Return on assets
-673%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-54,444.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CKPT stock price
How has the Checkpoint Therapeutics stock price performed over time
Intraday
-1.27%
1 week
4.46%
1 month
9.86%
1 year
24.47%
YTD
2.18%
QTD
4.46%
Financial performance
How have Checkpoint Therapeutics's revenue and profit performed over time
Revenue
$78,000
Gross profit
$78,000
Operating income
-$35.49M
Net income
-$42.47M
Gross margin
100%
Net margin
-54,444.9%
CKPT's net margin has dropped by 75% year-on-year but it is up by 29% since the previous quarter
Checkpoint Therapeutics's revenue has shrunk by 59% YoY but it has increased by 15% QoQ
CKPT's gross profit has plunged by 59% YoY but it is up by 15% from the previous quarter
Checkpoint Therapeutics's operating income has increased by 42% YoY and by 21% QoQ
Growth
What is Checkpoint Therapeutics's growth rate over time
Valuation
What is Checkpoint Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1,095.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,287.06
CKPT's EPS has surged by 65% year-on-year and by 31% since the previous quarter
The equity has plunged by 54% from the previous quarter but it has grown by 32% YoY
CKPT's price to sales (P/S) is 118% higher than its 5-year quarterly average of 508.0 and 70% higher than its last 4 quarters average of 653.7
Checkpoint Therapeutics's revenue has shrunk by 59% YoY but it has increased by 15% QoQ
Efficiency
How efficient is Checkpoint Therapeutics business performance
CKPT's return on sales has dropped by 75% year-on-year but it is up by 29% since the previous quarter
The return on assets has declined by 41% year-on-year but it is up by 10% since the previous quarter
Dividends
What is CKPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CKPT.
Financial health
How did Checkpoint Therapeutics financials performed over time
The total assets is 74% less than the total liabilities
The company's quick ratio has shrunk by 55% QoQ and by 4.2% YoY
The total assets has plunged by 53% from the previous quarter and by 32% YoY
CKPT's debt is 100% greater than its equity
The equity has plunged by 54% from the previous quarter but it has grown by 32% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.